Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adiponectin in T2DM and MAFLD Treatment
NCT07539584Completed
- Sponsor
- MONIKI
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in metabolic dysfunction associated fatty liver disease (MAFLD) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by MONIKI. Primary endpoint: Change in serum high-molecular-weight adiponectin levels at 6 months. Started Mar 2022; status: completed.
02
Conditions
metabolic dysfunction associated fatty liver disease (MAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07539584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539584.